Lv4
620 积分 2022-02-13 加入
HLA common and well‐documented alleles in China
1个月前
已完结
PK/PD Evaluation of Antibody–Drug Conjugates with Enhanced Immune Effector Functions
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8
3个月前
已完结
Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys
4个月前
已完结
Transferrin receptor–targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA
4个月前
已完结
Modern approaches to therapeutic oligonucleotide manufacturing
4个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
5个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
5个月前
已完结
皖公网安备34019202002308
